CLOs on the Move

Monogram BioSciences

www.monogrambio.com

 
Monogram Biosciences, Inc. (Monogram) is a life sciences company committed to advancing personalized medicine and improving patient outcomes through the development of molecular diagnostic products that guide and target the appropriate treatments
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Exela Pharma Sciences

Exela Pharma Sciences is a Lenoir, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Douglas Laboratories

Douglas Laboratories is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Top RX

If you think all generic pharmaceutical distributors are alike, it’s time to think again. We’re TOP RX, a leading national generic distributor that helps more than 5,000 pharmacies keep prices low on more than 2,800 generic pharmaceuticals. We call our company “TOP” for several reasons. We bring value to your business in many ways including our technological solutions, guaranteed product credibility and competitive pricing.

Neurotrope

Neurotrope is discovering restorative therapeutics for patients with life-altering neurodegenerative diseases and development disorders. We are a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer`s Disease, Fragile X Syndrome and Niemann-Pick Type C